Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine

New discovery of high-affinity SARS-CoV-2 spike S2 protein binding peptide selected by PhIP-Seq

Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines

The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2

Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Pre-Clinical Development of a Potent Neutralizing Antibody MW3321 With Extensive SARS-CoV-2 Variants Coverage

Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron

A Bacterially Expressed SARS-CoV-2 Receptor Binding Domain Fused With Cross-Reacting Material 197 A-Domain Elicits High Level of Neutralizing Antibodies in Mice

Cross-species tropism and antigenic landscapes of SARS-CoV-2 variants

A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy

A review of the safety and efficacy of current COVID-19 vaccines

Azacytidine targeting SARS-CoV-2 viral RNA as a potential treatment for COVID-19

A cell-penetrating whole molecule antibody targeting intracellular HBx suppresses hepatitis B virus via TRIM21-dependent pathway (vol 8, pg 549, 2018)

A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2